Literature DB >> 24128266

Evidence-based medicine: the design and interpretation of noninferiority clinical trials in veterinary medicine.

K J Freise1, T-L Lin, T M Fan, V Recta, T P Clark.   

Abstract

Noninferiority trials are clinical studies designed to demonstrate that an investigational drug is at least as effective as an established treatment within a predetermined margin. They are conducted, in part, because of ethical concerns of administering a placebo to veterinary patients when an established effective treatment exists. The use of noninferiority trial designs has become more common in veterinary medicine with the increasing number of established veterinary therapeutics and the desire to eliminate potential pain or distress in a placebo-controlled study. Selecting the appropriate active control and an a priori noninferiority margin between the investigational and active control drug are unique and critical design factors for noninferiority studies. Without reliable historical knowledge of the disease response in the absence of treatment and of the response to the selected active control drug, proper design and interpretation of a noninferiority trial is not possible. Despite the appeal of conducting noninferiority trials to eliminate ethical concerns of placebo-controlled studies, there are real limitations and possible ethical conundrums associated with noninferiority trials. The consequences of incorrect study conclusions because of poor noninferiority trial design need careful attention. Alternative trial designs to typical noninferiority studies exist, but these too have limitations and must also be carefully considered.
Copyright © 2013 by the American College of Veterinary Internal Medicine.

Entities:  

Keywords:  Ethics; Placebo; Positive control; Statistical methods

Mesh:

Year:  2013        PMID: 24128266     DOI: 10.1111/jvim.12211

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

Review 1.  Companion animals: Translational scientist's new best friends.

Authors:  Amir Kol; Boaz Arzi; Kyriacos A Athanasiou; Diana L Farmer; Jan A Nolta; Robert B Rebhun; Xinbin Chen; Leigh G Griffiths; Frank J M Verstraete; Christopher J Murphy; Dori L Borjesson
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

2.  Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.

Authors:  M Payne-Johnson; C Becskei; Y Chaudhry; M R Stegemann
Journal:  Vet Rec       Date:  2014-11-27       Impact factor: 2.695

Review 3.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

Review 4.  Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.

Authors:  Peter Lees; Pierre-Louis Toutain; Jonathan Elliott; Jerome M Giraudel; Ludovic Pelligand; Jonathan N King
Journal:  J Vet Pharmacol Ther       Date:  2022-04-22       Impact factor: 1.567

5.  Effectiveness of two intranasal vaccines for the control of bovine respiratory disease in newborn beef calves: A randomized non-inferiority multicentre field trial.

Authors:  N Masset; F Meurens; M Marie; P Lesage; A Lehébel; N Brisseau; S Assié
Journal:  Vet J       Date:  2020-08-19       Impact factor: 2.688

6.  Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease.

Authors:  Dietmar Hamel; Alexandra Richard-Mazet; Florian Voisin; Inge Böhne; Florence Fraisse; Renate Rauh; Rose Huang; Michael Kellermann; Laura Letendre; Pascal Dumont; Steffen Rehbein
Journal:  Vet Med Sci       Date:  2020-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.